Grifols (GIFLF) Interest Expenses (2010 - 2025)
Grifols' (GIFLF) quarterly Interest Expenses came in at -$727527.2 in Q4 2025, up 4.65% on a YoY basis from -$695225.2 in Q4 2024, and up 4.65% quarter-over-quarter from -$762977.1 in Q4 2024.
Analysis
Grifols (GIFLF) Interest Expenses (2010 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Interest Expenses for 15 consecutive years, with -$727527.2 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Interest Expenses rose 4.65% year-over-year to -$727527.2; the trailing twelve-month figure through Dec 2025 stood at $79.4 million (down 45.54% YoY), and the FY2025 full-year result was -$706.1 million, up 7.45% from the prior year.
- Interest Expenses improved to -$727527.2 in Q4 2025 per GIFLF's latest filing, from -$762977.1 in the prior quarter.
- Across five years, Interest Expenses topped out at $81.5 million in Q4 2021 and bottomed at -$762977.1 in Q4 2024.
- Historically, Interest Expenses has averaged $19.9 million across 4 years, with a median of -$684931.7 in 2023.
- The sharpest annual moves came in 2021 and 2024: Interest Expenses gained 24.18% in 2021, then slipped 18.78% in 2024.
- Over 4 years, Interest Expenses stood at $81.5 million in 2021, then slumped by 100.79% to -$642336.1 in 2023, then retreated by 18.78% to -$762977.1 in 2024, then grew by 4.65% to -$727527.2 in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered -$727527.2, -$762977.1, and -$642336.1 for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | -727,527.20 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -727,527.20 |
| Dec 31, 2024 | -762,977.12 |
| Dec 31, 2023 | -642,336.13 |
| Dec 31, 2021 | 81.54 Mn |
| Dec 31, 2020 | 65.66 Mn |
| Dec 31, 2019 | 65.38 Mn |
| Dec 31, 2018 | -334.74 Mn |
| Jun 30, 2018 | -247.31 Mn |
| Dec 31, 2017 | -310.07 Mn |
| Jun 30, 2017 | 76.41 Mn |
| Dec 31, 2016 | -64.32 Mn |
| Sep 30, 2016 | 68.29 Mn |
| Jun 30, 2016 | 71.44 Mn |
| Dec 31, 2015 | 52.46 Mn |
| Sep 30, 2015 | 67.25 Mn |
| Jun 30, 2015 | 64.73 Mn |
| Mar 31, 2015 | -68.65 Mn |
| Dec 31, 2014 | 74.88 Mn |
| Sep 30, 2014 | 71.27 Mn |
| Jun 30, 2014 | 73,016.50 |